One-third (31%) know of someone who has taken a GLP-1 for weight loss and 22% for Type 2 diabetes
However, the short half-life and dose-limited adverse gastrointestinal effects of GLP-1 have limited its clinical application
One study showed that some patients may also start drinking more water, creating the risk of polyuria among the elderly community
Patent filings have concentrated on sequence optimization, receptor balance, and dosing regimens [5, 6], while scientific reviews increasingly position these compounds as the next frontier beyond single-target GLP-1 therapy [1, 2]
The primary endpoint was a composite of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death
This Ozempic program has been a game-changer for me